Stock SOLARA SOLARA ACTIVE PHARMA SCIENCES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Solara Active Pharma Sciences Limited

Equities

SOLARA

INE624Z01016

Market Closed - NSE India S.E.
Other stock markets
 07:43:49 2024-05-02 am EDT 		5-day change 1st Jan Change
533.2 INR +0.10% Intraday chart for Solara Active Pharma Sciences Limited -2.63% +47.64%
Apr. 08 Solara Active Pharma Sciences Limited Approves Appointment of Mohan Muthunarayanan as an Executive Director CI
Mar. 26 Solara Active Pharma Gets Board Nod to Sell 100% Stake in SeQuent Penems MT

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Weaknesses

  • The company has insufficient levels of profitability.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
SOLARA ACTIVE PHARMA SCIENCES LIMITED Stock Solara Active Pharma Sciences Limited
+47.64% 230M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+30.23% 699B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.07% 571B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.66% 364B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.39% 326B
B-
ABBVIE INC. Stock AbbVie Inc.
+2.84% 286B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.68% 236B
B+
NOVARTIS AG Stock Novartis AG
+4.71% 198B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-12.43% 194B
A+
PFIZER, INC. Stock Pfizer, Inc.
-3.35% 154B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. SOLARA Stock
  4. Ratings Solara Active Pharma Sciences Limited